Jeffrey Strovel

430 total citations
24 papers, 340 citations indexed

About

Jeffrey Strovel is a scholar working on Molecular Biology, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Jeffrey Strovel has authored 24 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 10 papers in Hematology and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Jeffrey Strovel's work include Protein Degradation and Inhibitors (9 papers), Multiple Myeloma Research and Treatments (7 papers) and Histone Deacetylase Inhibitors Research (5 papers). Jeffrey Strovel is often cited by papers focused on Protein Degradation and Inhibitors (9 papers), Multiple Myeloma Research and Treatments (7 papers) and Histone Deacetylase Inhibitors Research (5 papers). Jeffrey Strovel collaborates with scholars based in United States, Japan and Australia. Jeffrey Strovel's co-authors include Makoto Yoshioka, Steven Fletcher, Mithun Raje, Lijia Chen, Jeremy L. Yap, Maryanna E. Lanning, Eishi Ashihara, J. Stamberg, Paul Yarowsky and Janak Padia and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jeffrey Strovel

23 papers receiving 338 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey Strovel United States 11 264 97 61 40 28 24 340
Colin A. Martz United States 4 208 0.8× 104 1.1× 83 1.4× 16 0.4× 46 1.6× 5 294
Anuradha Illendula United States 10 317 1.2× 191 2.0× 87 1.4× 20 0.5× 44 1.6× 19 435
David Cruz Hernandez United States 5 174 0.7× 76 0.8× 63 1.0× 13 0.3× 31 1.1× 7 252
Gabriele Greve Germany 10 368 1.4× 148 1.5× 92 1.5× 43 1.1× 70 2.5× 19 467
Stephen S.Y. Lam Hong Kong 9 172 0.7× 116 1.2× 61 1.0× 24 0.6× 46 1.6× 20 267
Arda Durmaz United States 10 145 0.5× 94 1.0× 66 1.1× 37 0.9× 71 2.5× 50 305
Normand Richard United States 7 300 1.1× 184 1.9× 64 1.0× 11 0.3× 29 1.0× 12 436
Theo Bijma Netherlands 8 401 1.5× 28 0.3× 46 0.8× 42 1.1× 14 0.5× 13 486
Amanda L. Robichaud United States 7 280 1.1× 36 0.4× 105 1.7× 52 1.3× 47 1.7× 9 370

Countries citing papers authored by Jeffrey Strovel

Since Specialization
Citations

This map shows the geographic impact of Jeffrey Strovel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Strovel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Strovel more than expected).

Fields of papers citing papers by Jeffrey Strovel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Strovel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Strovel. The network helps show where Jeffrey Strovel may publish in the future.

Co-authorship network of co-authors of Jeffrey Strovel

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Strovel. A scholar is included among the top collaborators of Jeffrey Strovel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Strovel. Jeffrey Strovel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kida, Takashi, Makoto Yoshioka, Keisuke Nishioka, et al.. (2021). CG223, a novel BET inhibitor, exerts TGF-β1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis. Pulmonary Pharmacology & Therapeutics. 70. 102057–102057. 10 indexed citations
3.
Yang, Shyh‐Ming, Makoto Yoshioka, Jeffrey Strovel, et al.. (2019). Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases. Bioorganic & Medicinal Chemistry Letters. 29(10). 1220–1226. 10 indexed citations
4.
Villar‐Prados, Alejandro, Sherry Y. Wu, Karem A. Court, et al.. (2018). Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Molecular Cancer Therapeutics. 18(2). 421–436. 10 indexed citations
5.
Mohamed, Ahmed A., Charles P. Xavier, Gauthaman Sukumar, et al.. (2018). Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth. Cancer Research. 78(13). 3659–3671. 44 indexed citations
6.
Yang, Shyh‐Ming, Daniel J. Urban, Makoto Yoshioka, et al.. (2018). Discovery and lead identification of quinazoline-based BRD4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 28(21). 3483–3488. 13 indexed citations
7.
Yoshioka, Makoto, Jay Chauhan, Susumu Nakata, et al.. (2017). CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model. Biochemical and Biophysical Research Communications. 484(2). 262–268. 17 indexed citations
8.
Strovel, Jeffrey, Nathan P. Coussens, Michael Hughes, et al.. (2016). Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies. 27 indexed citations
9.
Chen, Lijia, Jeremy L. Yap, Makoto Yoshioka, et al.. (2015). BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. ACS Medicinal Chemistry Letters. 6(7). 764–769. 73 indexed citations
10.
Nagao, Rina, Eishi Ashihara, Shinya Kimura, et al.. (2011). Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 – a novel Wnt/β-catenin signaling inhibitor. Cancer Letters. 312(1). 91–100. 18 indexed citations
11.
12.
Ohler, Zoë Weaver, et al.. (2007). Antiangiogenic properties of the IMPDH inhibitor AVN944. Cancer Research. 67. 3983–3983. 2 indexed citations
13.
Klisovic, Rebecca B., Guido Tricot, Steven Coutré, et al.. (2007). A phase I trial of AVN944 in patients with advanced hematologic malignancies. Journal of Clinical Oncology. 25(18_suppl). 14026–14026. 3 indexed citations
14.
15.
Sun, Mei, Vasantha Srikantan, Jia Li, et al.. (2006). Characterization of Frequently Deleted 6q Locus in Prostate Cancer. DNA and Cell Biology. 25(11). 597–607. 10 indexed citations
16.
Khalak, Hanif, et al.. (2005). Expression Biomarkers for Clinical Efficacy and Outcome Prediction in Cancer. Pharmacogenomics. 7(1). 105–115. 8 indexed citations
17.
Strovel, Jeffrey, J. Stamberg, W. Edward Highsmith, et al.. (2000). Plasma telomerase activity predicts response and relapse in lung cancer. Lung Cancer. 29(1). 258–258. 1 indexed citations
18.
Chase, Michael B., Susanne B. Haga, W. David Hankins, et al.. (1999). Binding of HMG-I(Y) elicits structural changes in a silencer of the human ?-globin gene. American Journal of Hematology. 60(1). 27–35. 24 indexed citations
19.
Strovel, Jeffrey, J. Stamberg, & Paul Yarowsky. (1999). Interphase FISH for rapid identification of a Down syndrome animal model. Cytogenetic and Genome Research. 86(3-4). 285–287. 15 indexed citations
20.
Strovel, Jeffrey, Lynne V. Abruzzo, W. Edward Highsmith, & Judith Stamberg. (1998). Quantitative measurement of telomerase activity in lymphadenopathy: correlation with histologic features and human immunodeficiency virus-1 infection.. PubMed. 11(10). 957–62. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Colin A. Martz Breakdown of academic impact, for papers by Anuradha Illendula Breakdown of academic impact, for papers by David Cruz Hernandez Breakdown of academic impact, for papers by Gabriele Greve Breakdown of academic impact, for papers by Stephen S.Y. Lam Breakdown of academic impact, for papers by Arda Durmaz Breakdown of academic impact, for papers by Normand Richard Breakdown of academic impact, for papers by Theo Bijma Breakdown of academic impact, for papers by Amanda L. Robichaud
Rankless by CCL
2026